HC Wainwright Predicts Zura Bio’s Q1 Earnings (NASDAQ:ZURA)

Zura Bio Limited (NASDAQ:ZURA) – Analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Zura Bio in a report released on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.21) per share for the quarter, down from their previous estimate of ($0.20). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Zura Bio’s Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.85) EPS.

Several other analysts also recently weighed in on the stock. Oppenheimer reiterated an “outperform” rating and issued a $19.00 price objective (down from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th. Guggenheim reaffirmed a “buy” rating and set a $15.00 price target on shares of Zura Bio in a report on Wednesday, March 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. Finally, Chardan Capital cut their target price on Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $14.67.

Zura Bio Stock Performance

ZURA stock opened at $1.13 on Monday. The stock’s fifty day moving average is $1.37 and its two-hundred day moving average is $2.57. The stock has a market capitalization of $77.26 million, a price-to-earnings ratio of -2.13 and a beta of 0.08. Zura Bio has a 1 year low of $0.97 and a 1 year high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.09. The company had revenue of $0.00 million for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ZURA. American Century Companies Inc. bought a new position in Zura Bio during the 4th quarter valued at $27,000. Prudential Financial Inc. acquired a new stake in shares of Zura Bio in the fourth quarter valued at $28,000. Two Sigma Advisers LP bought a new position in Zura Bio during the fourth quarter valued at about $32,000. ProShare Advisors LLC acquired a new position in Zura Bio during the fourth quarter worth about $35,000. Finally, XTX Topco Ltd bought a new stake in Zura Bio in the fourth quarter worth about $44,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.